ADVANCEMENTS IN PRRT FOR TREATING NEUROENDOCRINE TUMOURS AND OTHER CANCERS. A LOOK AT TAT
Neuroendocrine tumours (NETs) are heterogeneous with varying behaviour. Treatment decisions are taken basis Histological studies plus imaging data and clinical studies. Surgery is a curative option for NET patients with localized well-differentiated tumours, for non-localized metastatic tumours, Surgery is not an option. PRRT (Peptide Receptor Radionuclide Therapy) is a curative option for non-localised, heterogeneous, metastatic neuroendocrine tumours. PRRT has proven to be the most promising treatment modality amongst various systemic treatments such as Somatostatin Analogues, Chemotherapy, Molecular Targeted Treatments, Alpha Interferon etc. PRRT causes DNA damage to the tumour cells. In the 1990s PRRT was administered using the radiopeptide 111In-DTPA-octreotide (Octreoscan®), the responses were reasonable but the effects were not long-lived and there were long term adverse sequelae. Next PRRT agent to be developed was the more effective beta-emitting radionuclide Y90, sust